^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Evaluation of small extracellular vesicles as biomarkers of efficacy with anti-PD-1 mAb therapy in patients with recurrent/metastatic HNSCC.

Published date:
05/25/2023
Excerpt:
High PD-L1, but not PD-1 on TEX, was associated with better OS [HR: 0.15 (95% CI 0.04-0.56), P = 0.005]; and PFS: HR: 0.33 (95% CI 0.11-0.94), P = 0.04].
DOI:
10.1200/JCO.2023.41.16_suppl.6042
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Factors evaluated as predictors of exceptional response to PD-1 inhibitors in patients with head and neck squamous cell cancer

Published date:
11/09/2020
Excerpt:
11 patients were identified as exceptional responders, 9 of whom had metastatic spread to lung, liver or bones. 7 patients were treated for more than one year, and all achieved CR…three patients older than 75 had the highest PD-L1: 75% by TPS and 100% by CPS in two patients. TMB was found moderate or high in all 8 patients tested before starting immunotherapy. TP53 was found mutated both in tumor and in blood in all but 2 of the 10 tested patients...
DOI:
10.1136/jitc-2020-SITC2020.0251